We are conducting this study to learn more about how effective, safe and tolerable a study drug called AZD9977 is when used in combination with dapagliflozin, in treating participants with heart failure and CKD.
At minimum:
1) Participant must be 21 years of age or older
2) Documented diagnosis of stable symptomatic HF and and a medical history of typical symptoms and signs of HF in those who are currently receiving loop diuretic treatment
a. Typical symptoms associated with HF: breathlessness, orthopnoea, paroxysmal nocturnal dyspnoea, reduced exercise tolerance, fatigue, tiredness, increased time to recover after exercise.
3) Left ventricular ejection fraction < 60% documented by the most recent echocardiogram 2D or 3D or cardiac magnetic resonance imaging within the last 12 months prior to screening.